On 13 November 2013, orphan designation (EU/3/13/1205) was granted by the European Commission to Novartis Europharm Limited, United Kingdom, for human monoclonal antibody against human interleukin 13 for the treatment of eosinophilic oesophagitis.
The sponsorship was transferred to Novartis Europharm Limited, Ireland, in May 2018.
Human monoclonal antibody against human interleukin 13
|Disease / condition||
Treatment of eosinophilic oesophagitis
|Date of decision||
|Orphan decision number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.